Sentences with phrase «antibody pembrolizumab»

Treatment with the anti — PD - 1 antibody pembrolizumab yielded good long - term survival outcomes in a phase Ib trial of patients with advanced melanoma.

May 29, 2015 Pembrolizumab shows real promise against head and neck cancer Immunotherapy with the anti-PD-1 antibody pembrolizumab (Keytruda ®) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical Oncology (ASCO).

Favorable responses with minimal toxicities in monotherapy trials have led to the first melanoma studies of T - VEC in combination with the cytotoxic T - lymphocyte — associated antigen 4 inhibitor ipilimumab and, separately, with the programmed death 1 — blocking antibody pembrolizumab.

The phase II part of a phase Ib / II study (ClinicalTrials.gov identifier: NCT02263508; MASTERKEY - 265)[24] assessing the safety and efficacy of T - VEC in combination with the PD - 1 — blocking antibody pembrolizumab in previously untreated, unresected stage IIIB / IV melanoma is evaluating confirmed ORR by irRECIST at week 24.

Not exact matches

Treating patients with an antibody called pembrolizumab (sold under the brand name Keytruda) caused these T cells to increase in number, says coauthor Kellie Smith, a cancer immunologist at Johns Hopkins University.

We are currently waiting for the results of several trials including EORTC 1325 which is investigating pembrolizumab, a PD - 1 checkpoint blocking antibody, compared to placebo in the adjuvant setting.»

Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the University of Pennsylvania.

Ramuacirumab (CYRAMZA ®), an anti-VEGFR2 targeted antibody, is also appproved for esophageal cancer patients, while pembrolizumab (Keytruda ®), an anti-PD-1 checkpoint immunotherapy, is approved for patients with advanced cancers of the gastroesophageal junction that express PD - L1.

The FDA approved two anti-PD-1 antibodies (nivolumab / Bristol - Myers Squibb and pembrolizumab / Merck & Co.) for metastatic melanoma in 2014, and it extended approval to metastatic squamous non-small cell lung cancer earlier this year.